Request a Clarifi Demo    Click Here


From bench to bedside and beyond


Modulim is the leader in applying optical imaging platform powered by spatial frequency domain imaging (SFDI) with medical, agricultural, and industrial applications. We are dedicated to improving health, wellness, and quality of life of patients with chronic disease.

The seeds for Modulim were planted in 2002, when UC Irvine Physics undergraduate, David Cuccia, was exploring ways to more accurately characterize tissue. With the help of his mentors at the Beckman Laser Institute, David invented a new optical imaging technique, which he named spatial frequency domain imaging, or SFDI.


Convinced of its value to the research and medical communities, David dug deeper into this research, earning a Ph.D. focused on this technique, then worked independently to develop and refine the technology. In 2008, he started Modulated Imaging to commercialize SFDI and make it more broadly available to help researchers and healthcare providers around the world improve patient care and reduce costs.


Over the next few years, David and Amaan Mazhar, Ph.D., our VP of Research and Development, secured over $11 million in SBIR and STTR grants and contracts from the National Institutes of Health (NIH) and the Department of Defense (DOD) to refine the technology and explore a variety of applications.

In 2019, we changed the name of the company to Modulim — a contraction of modulated imaging — acknowledging that we are not just an imaging company. We’re a software company, a data/analytics company, and most important, a clinical solutions company, that is dedicated to managing and preventing complications of chronic disease.

Finding our feet


Reflect RS®

In 2012, we introduced Reflect RS to select customers in the translational research field. Reflect RS is a fully-loaded, turnkey hardware and software solution for detecting and visualizing spatially resolved optical and functional parameters (µa and µs’) of biological tissue. Customers use Reflect RS for everything from basic and pre-clinical research, to aesthetic imaging, and even agricultural applications.

Ox-Imager CS®

In 2016, we introduced an FDA-cleared medical version of the RS system called the Ox-Imager CS—indicated for use to determine oxygenation levels in superficial tissue for patients with potential circulatory compromise.


Clarifi™ Imaging System

In 2018, after putting our solution through its paces in real-world studies at the Keck School of Medicine of USC, the University of Arizona, and Kaiser Permanente, we distilled our learnings into a second-generation medical device—the Clarifi™ Imaging System.

Clarifi offers clinicians a powerful new diagnostic tool for assessing tissue heath consistently and objectively at a level not possible with any other technology.


With Clarifi, clinicians can more easily identify at-risk patients, quantify the nature and level of their risk, and stratify patients into appropriate care pathways to prevent the onset or escalation of complications from vascular compromise—like diabetic foot ulcers.

Putting our best foot forward


We were originally housed in the Photonic Incubator at the Beckman Laser Institute on the UC Irvine campus. In 2014, the company expanded to its first commercial space in San Juan Capistrano, but quickly outgrew this location. Today, Modulim operates out of a 8500 sq. ft. building, in Irvine, California close to the John Wayne airport. Our home includes office space, R&D labs, assembly, testing, and production.

The company we keep


From the very beginning—starting with the Beckman Laser Institute—numerous organizations have helped, nurtured, and supported our work in innumerable ways. Grants and other research support from the National Institutes of Health (NIH), the Department of Defense (DOD), and the National Science Foundation (NSF) enabled us to develop and refine the core platform technologies while exploring numerous potential applications.


More recently, several world-class companies and professional organizations have invested in the company and supported our efforts to commercialize the technology, refine our go-to-market strategy, and grow the organization.


We are deeply indebted to them all.